Clinical Trials Detail

Treating Patients With NSCLC and ALK Fusion Mutations That Has Been Surgically Removed

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Objective
CategoryInformation
Study #: E4512 - Alchemist
Anatomic Site: Lung
Histology: Non-Small Cell Lung Cancer (NSCLC)
Mutation: ALK Fusion
Stage: Stage IB (with tumor size >4cm), II, or IIIA (non-squamous)
Treatment Phase: Patients have undergone complete surgical resection of their cancer and have negative margins and registered to A151216.
Location:
Study Link: https://clinicaltrials.gov/ct2/show/NCT02201992?term=E4512&rank=1

Clinical Trial Categories

  • Lung